Page 14 - Demo

14 R&D and BreakthroughsCadila%u2019s core values of innovation are still evident in a number of ground-breaking achievements that are constantly changing the healthcare industry. The company has continuously pushed the envelope, from ThRabis (2022), which transformed rabies prevention with a simplified three-dose schedule, to Mycidac-C, which gave patients with lung cancer new hope, and Polycap, which redefined preventive care in cardiovascular health. Beyond these successes, Cadila%u2019s researchers are spearheading developments in digital therapeutics for chronic conditions like diabetes and hypertension, long-acting injectables to increase patient compliance, biosimilars, and innovative anti-infectives to combat antibiotic resistance. With more than 300 scientists running its research facilities, Cadila is rethinking the future of patient care rather than just creating new medications.The Digital EdgeCadila is incorporating digital transformation and artificial intelligence into all facets of its business operations to build a future-ready enterprise that seamlessly combines technology and healthcare. Predictive modeling and toxicity profiling driven by AI are accelerating research and development and reducing